See the full story in the original article.
Read the original on MarketWatch ↗
Keywords
healthcarevaluationpharmaceuticals
Open a keyword to see other news on the same topic.
Related news
- Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Alnylam shares have fallen more than 40% year to date, even though the company is now solidly profitable, with Q2 2026 GAAP net income of $164.5 million and revenue up 67% to $1.29 billion. The author attributes much of the selloff to two concerns: Alnylam cut its 2026 revenue guidance for Amvuttra and Onpattra to $4.2–4.5 billion from $4.4–4.7 billion as demand normalized after an initial surge of patients switching to Amvuttra, and disappointing Phase 3 results for Wainua in ATTR-CM raised worries about Alnylam's nucresiran. The author argues both concerns are overstated, since the two drugs use different mechanisms and Amvuttra sales continue to grow robustly. Of the 23 analysts who rated the stock over the past three months, 19 recommended buying, and the average 12-month price target implies 54% upside.
- Temporary Delays in siRNA Manufacturing Mask Codexis' (CDXS) High-Option Value
In its Q3 2026 investor letter, White Brook Capital highlighted Codexis (NASDAQ:CDXS), which makes enzymes used to manufacture siRNA-based medicines, and said the stock holds call options with favorable payouts. On October 21, 2026, the stock closed at $1.29 with a market capitalization of $141.26 million, down 20.86% year to date and trading within a 52-week range of $0.96 to $2.98. However, 2026 has been marked by delays: three CDMO partners, Bachem, Nitto Denko Avecia and Axolabs, were signed early in the year, but only one has completed its technology evaluation, and long-term contract negotiations are still ongoing. Permitting delays have also hit its GMP-standard standalone facility, which is now scheduled to start production at year-end 2027, and the target for half-kilogram siRNA batches has moved to the end of this year or early next year.
- New bipartisan bill aims to speed up clinical trials for rare disease treatments
Bipartisan Reps. Jake Auchincloss (D) and Morgan Griffith (R) introduced the "Faster Clinical Trials Act" to speed up studies of rare disease treatments, one week after the FDA unveiled a new initiative for these drugs. The bill would create a network of reusable clinical trial sites and a "Center for Clinical Trial Innovation" at the FDA, with up to $75 million in annual funding over five years. Its goal is to cut trial costs and enrollment time by at least 30%, and to let patients receive experimental drugs at their regular doctor's office, with progress tracked through Zoom, electronic health records or wearables. Griffith said this would also help patients who live hours away from medical centers.
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Changes to This $100 Billion Federal Drug Program Could Make Banks the Hidden Beneficiaries
A proposed overhaul of the $100 billion federal 340B drug-discount program would shift some discounts to rebates starting January 1, 2027, so hospitals must pay upfront and wait for reimbursement. In an illustrative example, an extra $10 million balance at 6% annual interest would cost about $50,000 per month, which could increase demand for credit lines from banks that already serve hospitals. The American Hospital Association estimates administrative costs could exceed $1 billion per year, compared with HRSA's $537 million estimate for submitting claims. The article notes the incremental lending demand is unquantified, and the program faces a lawsuit filed on October 9 after an earlier rebate pilot was blocked in December 2025. Banks would benefit only if added interest exceeds funding costs and credit losses.
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
Related markets
Latest news
- Did Wall Street forget about Tesla's Cybercab?
Yahoo Finance's Brian Sozzi discusses Tesla (TSLA)'s Cybercab expansion and its relevance amid a possible merger with SpaceX (SPCX). Elon pointed to 2 million cumulative unsupervised robotaxi miles by quarter-end, Austin operating hours now run 6:00 a.m. to midnight, and more Cybercabs are expected in more cities in coming months. The Austin Cybercab fleet has grown by a factor of 10 since launch about a month ago. Tesla shares fell partly because the company cut capex by $5 billion, which Sozzi attributes to Optimus robot production bottlenecks rather than the Cybercab. He argues that with merger talks being explored, investors should start thinking of SpaceX and Tesla as one company.
- Crypto for Advisors: Stablecoins are ready for prime time
CoinDesk's Crypto for Advisors newsletter cites an EY-Parthenon 2026 Blockchain Payments Survey of 521 corporate and financial institution decision-makers. It found 18% of corporates have used stablecoins in production, double the 2025 share, while 15% report adopting tokenized deposits. Some 69% of financial institutions offer or plan to launch stablecoin services within two years, up from 30% in 2025. Cross-border business payments are the leading use case, and 45% of corporates and 53% of financial institutions favor using both stablecoins and tokenized deposits. Corporates strongly prefer blockchain payments integrated into existing banking interfaces (74%), and 63% would likely adopt them if offered by their current bank or payments provider.
- Is USA Rare Earth Stock a Once-in-a-Generation Reshoring Opportunity?
The article examines whether USA Rare Earth (USAR) can help the U.S. and its allies secure critical minerals, given China's dominance in rare-earth extraction and processing. China banned rare-earth exports in October 2025 in response to U.S. tariffs and chip restrictions; the ban was later temporarily lifted, though some Chinese companies have canceled U.S. exports, and China has also banned technology exports to USA Rare Earth and MP Materials. USAR shares are down roughly 15% in 2026 and about 74% from their lifetime high last October. Excluding the recently acquired Brazil-based Serra Verde, the company is essentially pre-revenue, though U.S. government supply agreements offer some pricing floor protection. With a market cap of roughly $4 billion and a target of about $1.8 billion in EBITDA for 2030, the author sees a worthwhile risk-reward profile for risk-tolerant investors, while stressing the stock is not low-risk.
- Nebius Declines 6% Despite Fresh Citi Financing; CoreWeave Drops 5%, Cloudflare Edges Higher
Nebius (NBIS) fell 6% to $162.03 despite a new senior secured credit facility from Citi, which matures in just under a year and is meant to fund data center development and GPU purchases while the company seeks longer-term asset-backed financing. CoreWeave (CRWV) dropped 5% to $58.86, while Cloudflare (NET) rose 2% to $313.35, with the article framing the selling as concentrated among neoclouds that rely on debt. A Barclays strategist noted that AI-spending credit stress has stayed largely confined to neocloud companies. Nebius has $37.5 billion in remaining performance obligations, $8.13 billion in capital spending, and three customers each accounting for a double-digit share of quarterly sales. The article says the Citi line adds to leverage concerns, making the timing and terms of the next financing a key test.
- How agentic AI shopping changes consumer staples: P&G CFO
P&G reported strong first-quarter earnings and reiterated its full-year revenue forecast. In an interview with Yahoo Finance, CFO Andre Schulten said that people using its products remains the core of the business, but the consumer's path to purchase is changing as AI agents buy on people's behalf, so P&G is proactively working out how agent-to-agent marketing works and how to distribute brand information. He said the company is also using decades of collected data and simpler algorithms to speed up molecule discovery, automate data extraction and analysis, and make forecasting more efficient. On marketing, he said algorithms weigh credibility, so P&G plans to publish and make accessible its scientific publications, independent studies and consumer reviews, an approach he believes gives big brands an advantage.
- SpaceX Just Became an AI Company. The Numbers Prove It.
SpaceX reported third-quarter revenue up 161% year over year to $14.6 billion and net income of $4.4 billion, making it profitable. Its AI segment, now called 'super intelligence (SI),' generated $7.6 billion in revenue, up 830% year over year and 195% sequentially, making it just over half of sales and the largest revenue source. Connectivity remains the most profitable segment with $2.4 billion in operating income, versus $431 million for SI, which lost $1.26 billion last quarter. SI accounted for $16.4 billion of the company's $19.6 billion in Q3 capital expenditures, but the results should ease concerns that it is a money pit, as cloud agreements with Alphabet and Anthropic and $608 million of Cursor revenue since its August acquisition show the investments are paying off. The author notes the stock remains richly valued.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.